

References

- Abdel-Hakim A.M., Badrawy H., Gemaei S., Ragab G.M., Helmy N.A. and Soliman M.A. (1989):** Bronchoalveolar lavage cellularity in uncontrolled insulin dependant diabetics. Egypt. J. Chest. Dis. Tub., 36 (1): 93.
- Abdel-Hakim AM; Hassanin K, Hussein MoF. and Ahmed F.Ao (1995):** Value of fiberoptic bronchoscopy in early bacteriologic diagnosis of suspected pulmonary tuberculosis. Egypt. J. Chest Dis. Tub., 44, 2: 125-130.
- Abe C., Hirano K., Wada Mo, et al. (1993):** Detection of M.TB in clinical specimens by PCR and Gen-Probe amplified M.TB Direct Test. J. Clin. Microbiol., 31: 3270-4.
- Affronti L.F. , Fife EoFS- and Grow. (1973):** Serodiagnostic test for tuberculosis Am Rev Respir. Dis., 107: 822.
- Alcaide F, Benítez MA, Martín R, Escribà JM. (2000):** Evaluation of the BACTEC MGIT 960 and MB BAC/T system for routine detection of Mycobacterium tuberculosis. J Clin Microbiol; 38: 3131-2.
- Al-Helaly A ., Hamdy A.B., Negm 1\1. and El-Nassany M. (1991):** Incidence of primary resistance to first row drugs used in treatment of pulmonary. Tuberculosis in Dakahlia Governorate. Egypt. J. Chest Tub., 38, I: 33-44.
- Al-Moamary MS (1999):** The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest, 116:726–731.
-

American Thoracic Society (1994): Treatment of tuberculosis. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment. *Am J Respir Crit Care Med.*, 149: 1359-1374.

American Thoracic Society and Centers for Disease Control (1981): Tuberculin skin test. *Amer. Rev. Respir. Dis.*, 124: 356. J

American Thoracic Society, Centers for Disease Control (1999): The tuberculin test. *Am Rev Resp Dis*; 124: 356.

American Thoracic Society, Centers for Disease Control and Prevention (1994): Treatment of tuberculosis and tuberculosis infection in adults and children. *Am. J Respir. Crit. Care Med.*;149:1359-1374.

American Thoracic Society/Centers for Disease Control and Prevention (1992): Control of tuberculosis. *Am Rev Respir Dis.*, 146: 1623-1633.

Andrews RH, Jenkins PA, Marks J, Pines A, Selkon JB, Somner AR (1974): Treatment of isoniazid-resistant pulmonary tuberculosis with ethambutol, rifampicin and capreomycin: a co-operative study in England and Wales. *Tubercle*;55:105—113.

Anglaret X., Saba J., Perronne C., et al., (1994): Empiric antituberculosis treatment: benefits for earlier diagnosis and treatment of tuberculosis. *Tuberc Lung. Dis.*, 75: 334-40.

Anonymous. Paserâ granules (2000): In. Physicians' desk reference, 54th edition. Montvale, NJ: Medical Economics Company,:1443-1445.

- Appel GB, Neu HC (1977):** The nephrotoxicity of antimicrobial agents [second of three parts]. *N Eng. J. Med.*;296:722—728.
- Aquinas M, Citron KM (1972):** Rifampicin, ethambutol, and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years' chemotherapy. *Tubercle*;53:153—165.
- ATS (1990):** American Thoracic Society, Diagnostic standards and classification of tuberculosis. *Am Rev Respir Dis.*, 142: 725-30.
- Baciewicz AM (1985):** Self TH. Isoniazid interactions. *South Med J*;78:714-718.
- Badawy AA (1999):** Study of HIV infections among pulmonary tuberculous patients in Sharkia Governorate. Thesis for Master Degree in Chest Diseases Zagazig University.
- Baganha M.F., Mota-pinto A., Pego A. (1992):** Neopterin in tuberculous and neoplastic pleural fluids. *Lung*, 170: 155-61.
- Ball P, Tillotson G. (1995):** Tolerability of fluorquinolone antibiotics: past, present, and future. *Drug Saf*;13:343-358.
- Banerji D, Andersen S. (1963):** A sociological study of awareness of symptoms among persons with pulmonary tuberculosis. *Bulletin of the World Health Organization*, 29:665—683.
- Barnum HN. (1986):** Cost savings from alternative treatments for tuberculosis. *Social Science and Medicine*, 23:847—850.
- Baron E.J., Peterson L.R. and Finglod S.M. (eds) (1990):** Baily and Scott Diagnostic Microbiology, 9th edition, p. 354.
-

- Bass J.B. and Serio R.A. (1981):** The Use of repeated skin tests to eliminate the booster phenomenon in serial tuberculin testing Am. Rev. Respir. Dis., 123: 394-396.
- Bates J.H., Stead W.W. (1993):** The history of tuberculosis as a global epidemic. Med. Clin. N. Am, 77: 1205-1217.
- Bayer R and Wilkinson D (1995):** Directly observed therapy for tuberculosis: history of an idea. Lancet, 345: 1545-1548.
- Berlin a.G.w. (1986):** Mycobacteria. In: "baily a~d scotte's Diagnostic Microbiology 8th edition. Baron, E.J. and Finegold, S.M. (cds).p. 577, The CI\1Vosby Cornpany.
- BMJ (1952):** The prevention of streptomycin resistance by combined chemotherapy. Medical Research Council. British Medical Journal,1157–1162.
- Bobrowitz ID, Robins DE. (1966):** Ethambutol--isoniazid versus PAS--isoniazid in original treatment of pulmonary tuberculosis. Am Rev Respir Dis;96:428-438.
- Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS (2002):** A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J. Respir. Crit. Care Med; 165:1526-1530.
- Body BA, Warren NG, Spicer A, et al. (1990):** Use of Gen-probe and BACTEC for rapid isolation and identification of mycobacteria. Am J Clin Pathol., 93: 415.
-

- Borgdorff MW, Floyd K, Broekmans JP. (2002):** Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. *Bulletin of the World Health Organization*, 80:217–227.
- Borut T.C Ank B.J. and Card S.L (1980):** Tetanus toxoid in children c-orrelation with in vitro lymphocyte stimulation and monocyte dwmot is. *LPediatr.* 97: 567.
- British Thoracic Society and Tuberculosis Association (1978):** A study of a standardized contact procedures in tuberculosis. *Tub Lung Dis.*, 59: 245.
- British Thoracic Society and Tuberculosis Association (1992):** A controlled trial of six months chemotherpay in pulmonary tuberculosis. *Am Rev Respir Dis.*, 126: 460-462.
- Broekmans, .I.E. (1994):** Control strategies and programme management intuberculosis, back to future. *Chichtester*, pp. 171-179.
- Brudney K and Dobkin J (1995):** Resurgent tuberculosis in New York city: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. *Am Rev Respir Dis.*, 144: 745-749.
- Brudney K. and Dobkin J. (1991):** Resurgent tuberculosis in New York City: fly, Homelessness, and the decline of tuberculosis control programs. *Am. Rev. kespir. Dis.*, 144: 745-9.
- Brunello F, Favari F, Fontana R. (1999):** Comparison of the MB/BacT and BACTEC 460 TB systems for recovery of mycobacteria from various clinical specimens. *J Clin Microbiol*; 37: 1206-9.
-

- Bureau of Tuberculosis Control (1999):** Clinical policies and protocols, 3rd edition. New York: Bureau of Tuberculosis Control, New York City Department of Health;55-57.
- Cameron E.WJ (1978):** Tuberculosis and mediastinoscopy, Thorax, 33: 117.
- Canadiass Thoracic Society (1996):** Canadian Tuberculosis Standards. Canadim Lung Association Ottawa.
- Catazaro A, Davidson BL, Fujiwara PI and Goldberger MJ (1997):** Rapid diagnostic tests for tuberculosis. Am J Respir Crit Care Med., 155: 1804-1814.
- Cawthorne T, Ranger D. (1957):** Toxic effect of streptomycin upon balance and hearing. BMJ;1:1444-1446.
- Centers for Disease Control and Prevention (1992):** Management of persons exposed to multidrug-resistant tuberculosis. MMWR, 41: 59-71.
- Centers for Disease Control and Prevention (1997):** Recommendations for counting reported tuberculosis cases. Centers for Disease Control and Prevention, 66: 20-25.
- Centers for Diseases Control and Prevention (1994):** Core curriculum on tuberculosis: what the clinician should know.
- Chaulet, P.; Boulahbal, F. and Grosse, J. (1995):** Surveillance of drug resistance for tuberculosis control: why and how? Tubercle and Lung Disease, 76: 487-492.
-

- Chaulk CP, Kazandjian VA (1998):** Directly observed therapy for treatment completion of pulmonary tuberculosis. *JAMA*, 279: 943-948.
- Chaulk CP, Moore-Rice K, Pizzo R and Chaisson RE (1995):** Eleven years of community based directly observed therapy for tuberculosis. *JAMA*, 274: 945-951.
- China Tuberculosis Control Collaboration (1996):** Results of directly observed short-course chemotherapy in 112 chinese patients with smear-positive tuberculosis. *Lancet*, 347: 358-362.
- Chowdhury AMR (1997):** Control of tuberculosis by community health workers in Bangladesh. *Lancet*, 350:169–172.
- Cohen R, Muzaffar S, Capellan J, et al. (1996):** The validity of classic symptom and chest radiographic configuration in predicting pulmonary tuberculosis. *Chest*, 109: 420-3.
- Collins C.H., grnagc J.1Yi. and Yates M.D. (1985):** Organization and practice in tuberculosis.
- Combs DL, O'Brien RJ and Geiter LJ (1990):** Tuberculosis short-course therapy trial: effectiveness, toxicity, and acceptability. The report of the final results. *Ann intern Med.*, 112: 397-406.
- Cooper A.M. and Flynn J.A. (1995):** The protective immune response to mycobacterium tuberculosis. *Curr. Opin. Immunol*, 7: 512-516.
- Corfton J. and Douglas (1989):** Clinical features of tuberculous. In: Seaton A, Asseaton D, and Leitch AG (eds) "Crofton and Douglas's Respiratory Disease" 4th edition p. 395, Blackwell scientific Publication.
-

- Crawford JT (1995):** New developments for the diagnosis of tuberculosis: The impact of molecular biology. In: Rossman MD, MacGregor RR (eds). Tuberculosis: clinical management and new challenges, McGraw-Hill Inc., 255-73.
- Croft RA and Croft RP. (1998):** Expenditure and loss of income incurred by tuberculosis patients before reaching effective treatment in Bangladesh. *International Journal of Tuberculosis and Lung Disease*, 2:252–254.
- Crofton J. (1962):** The contribution of treatment to the prevention of tuberculosis. *Bulletin of the International Union Against Tuberculosis*, 32:643–653.
- D’Esopo ND (1982):** Clinical trials in pulmonary tuberculosis. *Am Rev Respir Dis.*, 125: 85-93.
- Damato JJ, Collins MT, Rothlauf MV, McClatchy JK. (1983):** Detection of mycobacteria by radiometric and standard plate procedures. *J Clin Microbiol*; 17: 1066-73.
- David H.L. (1970):** probability distribution of drug-resistant mutants in unselected population of mycobacterium tuberculosis. *Appl Microbiol.*, 810-814.
- David H.L. (1976):** bacteriology of the mycobacterioses. Government printing office. Washrngton DC, USA.
- De Cock KM and Chaisson RE. (1999):** Will DOTS do it? a reappraisal of tuberculosis control in countries with high rates of HIV infection. *Int J Tuberc Lung Dis*; 3: 457-65.
-

- Devadatta S (1966):** Comparative value of sputum smear examination and culture examination in assessing the progress of tuberculosis patients receiving chemotherapy. Bulletin of the World Health Organization, 34:573–587.
- Dholakia R and Almeida J. (1997):** The potential economic benefits of the DOTS strategy against TB in India. Geneva, World Health Organization, (document WHO/TB/96.218).
- Dickinson JM and Mitchison DA. (1981):** Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis;123:367-371.
- Divinagracia R. and Harris H.W. (1999):** Miliary tuberculosis. In: Tuberculosis and non tuberculosis mycobacterial infection. Schlossberg D. (eds) 4th edition, W.E. Saunders Company. London, P.: 271.
- Doster B, Murray FJ, Newman R, Woolpert SF. (1973):** Ethambutol in the initial treatment of pulmonary tuberculosis. Am Rev Respir Dis;107:177—190.
- Duboczy B.O. and White F.e. (1966):** Latex agglutination test for tuberculosis. Am. Rev. Respir. Dis., 94: 914.
- Dunlap NE and Briles DE (1993):** Immunology of tuberculosis. Med Clin North Am., 77 (6): 1235-51.
- Dutt AK, Mehta JB, Whitaker BJ, et al. (1998):** Outbreak of tuberculosis in a church. Chest 107 (2): 447-52.
- Dye C (1998):** Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet, 352:1886–1891.
-

- Dye C (1999):** Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. *Journal of the American Medical Association*, 282:677–686.
- Dye C, Watt CJ, Bleed DM, Mehran Hosseini S, Raviglione MC. (2005):** Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. *JAMA*; 293: 2767-75.
- Eighoul, M.T.; Goshi, R.M. and Rizghalla, T. (1989):** Primary and acquired drug resistance in mycobacterium tuberculosis strains in western region of Gama hiriya Trop. Geogr. Med., 41 (4): -304-308.
- Ellard GA. (1999):** The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency. *International Journal of Tuberculosis and Lung Disease*, 3:S322–S324.
- Elliott AM and Foster SD (1996):** Diagnosis of tuberculosis by DNA amplification in clinical practice evaluation. *Tubercle Lung Dis.*, 77: 27-29.
- Enarson DA, Rieder HL, Arnadottir T and Trebucq A (1996):** Tuberculosis guide for low income countries. *International Union Against Tuberculosis and Lung Disease*, 110: 407-415.
- Erlich HA, Gelf DH and Sninsky JJ (1991):** Recent advances in PCR. *Science*, 252: 1643.
-

- Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC. (2000):** Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcome in six countries. *JAMA*;283:2537—2545.
- Fairly IM and Heap BJ. (1989):** Pulmonary tuberculosis in Gurkhas in Hong Kong in the period 1984–1987 and the role played by routine radiology in case detection. *Journal of the Army Medical Corps*, 135:31–32.
- Farmer P and Kim JY. (1998):** Community based approaches to the control of multidrug-resistant tuberculosis: introducing “DOTS-plus”. *British Medical Journal*, 317:671–674.
- Fishman Ap (1998):** Approach to the patient with respiratory symptoms, *Fishman’s Pulmonary Diseases and disorders*, 3rd edition, Eds: AP Fishman et al, McGraw Hile, New York, St Louis. P 370.
- Floyd K, Wilkinson D, Gilks C. (1997):** Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa. *British Medical Journal*, 315:1407–1411.
- Fox W, Ellard GA, Mitchison DA. (1999):** Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. *International Journal of Tuberculosis and Lung Disease*, 3:S231–S279.
-

- Fox W. (1981):** Self administration of medicament. A review of published work and a study of the problems. *Tubercle.*, 31: 307-310.
- Fox W. (1992):** Bulletin of the international union against tuberculosis. 48: 49.
- Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B (1996):** A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. *JAMA*;276:1229—1235
- Fryatt RJ. (1997):** Review of published cost effectiveness studies on tuberculosis treatment programmes. *International Journal of Tuberculosis and Lung Disease*, 1:101–109.
- Fuchs D., Hausen A., Kofler et al, (1984):** Neoprotein as an index (,f immune response in patients with tuberculosis. *Lung*, 162: 33746.
- Fujiwara PI (1999):** Clinical policies and protocols. New York: Bureau of Tuberculosis Control, New York City Department of Health.
- Fujiwara PI and Sherman LF (1997):** Multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis.*, 1: 279-298.
- Gangadharam, P. (1984):** Drug resistance in mycobacteria. Florida: CRC Press, p. 7.
- Garfield JW, Jones JM, Cohen NL, Daly JF, McClemont JH. (1966):** The auditory, vestibular, and renal effects of capreomycin in humans. *Ann N Y Acad Sci*;135:1039-1046.
-

- Ghari b M.A. (1979):** Evaluation of different staining methods diagnosis of tuberculous infection. M.Sc. Thesis in Microbiology. Cairo University.
- Girling DJ. (1982):** Adverse effects of antituberculous drugs. *Drugs*;23:56-74.
- Glynn, J.R.; Jeukias, P.A. and Warndorf, D.K. (1995):** Patterns of initial and acquired antituberculosis drug resistance in Karonga District, Malwai, *Lancet*, 345: 907-10.
- Goble, M.; Iseman, M.D. and Madsen, L.A. (1993):** Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. *N, Engl. J Moo*; 329: 527-532.
- Good R.C. and Mastro T.D.(1989):** Laboratory how it can help the clinician clinics in chest. *Med. Vol. 10, No.3*, p. 315-322.
- Grange JM, Gibson J, Nassau E and Kardjito T (1980):** Enzyme-linked immunosorbent assay: a study of antibodies to M.TB in the IgG, IgA, IgM. *Classes in tuberculosis. Sarcoidosis and grohn's disease. Tubercle*, 61: 145-168.
- Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. (1995):** Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of *Mycobacterium avium* complex lung disease. *Clin Infect Dis*;21:594-598
- Grosset J. (1980):** Bacteriological basis of short Course chemotherapy for tuberculosis. *Clin chest med*; 1:231.
-

- Gupta R, Cegielski JP, Espinal MA (2002):** Increasing transparency in partnerships for health-introducing the Green Light Committee. *Trop Med Int Health*; 7: 970-6.
- Hafner R, Cohn JA, Wright DJ, Dunlap NE, Egorin MJ, Enama ME, Muth K, Peloquin CA, Mor N, Heifets LB (1997):** Early bactericidal activity of isoniazid in pulmonary tuberculosis. *Am J Respir Crit Care Med*;156:918—923
- Helwitt J., Goates AR.M. and Harboe M. (1990):** Characterization of monoclonal antibodies in tuberculous patients. *J. Clin. Microbial.*, 56: 468.
- Hirano, K., Kazumi, Y. and Abd, C. (1996):** Resistance to antituberculosis drugs in Japan. *Tubercle*, 77:130-135.
- Hong Kong Chest Service/British Medical Research Council (1989):**
A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum smear negative pulmonary tuberculosis: results at 5 years. *Am Rev Respir Dis*;139:871—876
- Hong Kong Chest Service/British Medical Research Council (1991):**
Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. *Am Rev Respir Dis*;143:700—706
- Horn DL, Hewlett D, Alfalla C, Peterson S, Open SM (1994):** Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. *N Engl J Med.*, 330: 1241.
-

- Hyland K. and Howells D.W. (1988):** Analysis and clinical significance of pterins. *J. Chromatogr.*, 429: 95-121.
- Int J Tuberc Lung Dis (2006):** Tuberculosis Research Centre, Chennai, India.; 10 (3): 346-8 .
- International Journal of Tuberculosis and Lung Disease (2001):** Revised international definitions in tuberculosis control., 5:213–215.
- Invanyi L., Daminai G., and Beltrame A. (1991):** Detection of IgG in tuberculous patients by monoclonal antibodies. *Am, Re, Respi . Dis.*, 149: 635.
- Jenner PJ, Ellard GA, Allan WG, Singh D, Girling DJ, Nunn AJ. (1981):** Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore. *Tubercle*;62:175—179
- Jindani A, Aber VR, Edwards EA, Mitchison DA (1980):** The early bactericidal activity of drugs in patients with pulmonary tuberculosis. *Am Rev Respir Dis*;121:939—949
- Karel Styblo (1999):** Fixed dose combination of anti-tuberculosis medications to prevent drug resistance. *Ann. Intern. Med.* 122:951-954.
- Kekkaku, H. (2006):** Research Institute of Tuberculosis, Japan Anti-Tuberculosis, Association, Tokyo, Japan.; 81 (10): 591-602
- Kent P.T. and Kubica G.P. (1985):** Public health mycobacteriology: ,1 guide for the level TII laboratory. Center for Disease Control Atlanta, Georgia.
-

- Khatrri GR and Frieden TR. (2000):** The status and prospects of tuberculosis control in India. *International Journal of Tuberculosis and Lung Disease*, 4:193–200.
- Knight L. (2000):** Tuberculosis and sustainable development. Geneva, World Health Organization, (document WHO/CDS/STB/2000.4; Stop TB Initiative series).
- Kochi A. (1991):** The global tuberculosis situation and the new control strategy of the World Health Organization. *Tubercle*, 72:1–6.
- Kochi, A. (1994):** Focus on problems. *Tuberculosis: distribution, risk factors, mortality immunobiol.*, 191: 325-336
- Kritski, A.L.; Rodrigues Dejesus, L.J.; Andrade, M.K. et al. (1997):** Retreatment tuberculosis cases, factors associated with drug resistance and adverse outcomes. *Chest*; Ill: 1162-1167.
- Kubica G.P .. Jones W. and Cater J.C. (1996):** Differential identification of mycobacteria. *Am. Rev. Res. Dis.* 24: 400. Quoted from T,ukaml11ra, M.(1981): A review of the methods of identification and differentiation of mycobacteria *Rev. Infect. Dis.*, 3: 841.
- Laid L.M. (1989):** Mycobacterium, tubercle bacilli. In: Mackie and McCarthy (eds). *Practical Medical Microbiology*. Churchill Livingstone, Edinburgh London and New York, 13th edition. vol. 2, ch. 25, p. 399.
- Larbaoui D. (1985):** Present state of chemotherapy of tuberculosis in high prevalence countries the present state of short course chemotherapy, 60-17
-

- Laverdiere M, Poirier L, Weiss K, Beliveau C, Bedard L, Desnoyers D. (2000):** Comparative evaluation of the MB/BacT and BACTEC 460 TB systems for the detection of mycobacteria from clinical specimens: clinical relevance of higher recovery rates from brothbased detection systems. *Diagn Microbiol Infect Dis*; 36: 1-5.
- Lawlor DA, Dickel CD, Hauswirth WW and Parpham P (1991):** Ancient HLA genes from 7500 year old archeological remains. *Nature*, 34: 785-788.
- Ledru, S.; Cauchoux, B. and Yameogo, M. (1996):** Impact of short-course therapy on tuberculosis drug resistance in south-west Burkina Faso, *Tubercle* 77, 429-436.
- Leibold JE. (1966):** The ocular toxicity of ethambutol and its relation to dose. *Ann N Y Acad Sci*;135:904—909
- Leitch AG (2000):** Pulmonary tuberculosis: Clinical features. In Crofton and Douglas's respiratory diseases, Seaton A. et al. (eds) 5th edition, Blackwell Scientific Publication London, pp. 507
- Long, R.; Chomye, S.; Dre, E. and Sitar, D.S. (2000):** Pseudo treatment failure of pulmonary tuberculous patient in association with a tuberculoma *can respir J* 2000 Jan-Feb: 7 (1) 79-83.
- Lordi GM and Riechman LB (1999):** Tuberculin skin testing. In tuberculosis and non tuberculous mycobacterial infections, Schoolssberg D, M.D. (eds) 4th edition, W.B. Saunders division of Harcourt Brace and Company London. Ch. 5, pp. 65.
-

- Madras (1969):** A controlled trial of 8 month, 6 month regimens of chemotherapy for sputum. Smear-positive pulmonary tuberculosis. *Am Rev Respir Dis.*, 139: 871-876.
- Mahmoudi A and Iseman MD. (1993):** Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. *JAMA*;270:65—68
- Marrero A (2000):** Towards elimination of tuberculosis in a low-income country: the experience of Cuba, 1962–97. *Thorax*, 55:39–45.
- Martin DJ and Gelfand EW (1981):** Biochemistry of diseases of immuno-development. *Ann Rev Biochem.*, 50: 845-77.
- Martinez E, Collazos J, Mayo J. (1999):** Hypersensitivity reactions to rifampin. *Medicine (Baltimore)*;78:361—369
- Massaro D., Katz S. and Sachs M. (1964):** Choroidal 1'13: a clue to hematogenous tuberculosis. *Am. Intern. Med.*, 60: 231.
- McNicol M.W. (1990):** Clinical features and management of tuberculosis. In: Brewis RAL, Gibson GJ, Geddes DM (ed). *Respiratory medicine*. London England: bailliere Tindall, 984-1018.
- McNicol MW, Campbell IA and Jenkins PA (1995):** Tuberculosis clinical features and management. In *Respiratory Medicine*, Brewis R.A.L. et al. (eds) 2nd editions W.B. Saunders Company L7D, London, 30 (20): 805.
-

- Menzies D.(1999):** Interpretation of repeated tuberculin tests (Boosting. conversion and reversion). Am. J. Respir and Crit Care Med. Vol., 159: 15-25 .
- Middlebrook G, Reggiardo Z, Tigert WD. (1977):** Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis; 115: 1066-9.
- Miller W.T. and Miller W.T. (1993):** Tuberculosis in normal host Semin. Roentgenol., 28: 109.
- Minnikin DE, Bolton RC, Hartmann S, et al. (1993):** An integrated procedure for the direct detection of characteristic lipids in tuberculosis patients. Ann. Soc. Belg Med Trop, 73 (Suppl 1): 13-24.
- Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD. (1976):** Isoniazid liver injury: clinical spectrum, pathology and probably pathogenesis. Ann Intern Med;84:81—192
- Mitchison DA (1985):** The action of antituberculosis drugs in short-course chemotherapy. Tubercle., 66: 219-225.
- Mitchison DA (1998):** How drug resistance emerges as a result of poor compliance during shortcourse chemotherapy for tuberculosis. International Journal of Tuberculosis and Lung Disease, 2:10–15.
- Mona EL Said Metwaly Madkor (2002):** A study on the efficacy of directly observed treatment with short course chemotherapy in treatment of the pulmonary tuberculos.
-

- Morgan MA, Horstmeier CD, De Young DR, Roberts GD. (1983):** Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol; 18: 384-8. thesis submitted in partial fulfilment of master degree of chest diseases, Zagazig university.
- Moulding T, Dutt AK and Reichman LB (1995):** Fixed dose combination of antituberculous medications to prevent drug resistance. Am Intern Med., 122: 951-954.
- Munt P.W. (1971):** Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults. Medicine, 51: 139.
- Murray CJL and Lopez AD (1996):** The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA, Harvard School of Public Health on behalf of the World Health Organization and the World Bank, (Global Burden of Disease and Injury Series, Vol. I).
- Murray CJL, Syblo K, Rouillon A (1990):** Tuberculosis in developing countries : Burden , intervention And cost . Bull int – union tuberc lung Dis ., 65:6.
- Murray CJL, Dejonghe E, Chum HJ (1991):** Cost effectiveness of chemotherapy for pulmonary tuberculosis in developing countries. Lancet, 338: 1305-1308.
- Nicholls A.C. (1975):** A serodiagnostic test for tuberculosis. J. Clin. Pathol., 28: 850.
-

- Noel AB, Cicquel B, Lecossur D (1989):** Rapid diagnosis of TB by amplification of mycobacterial DNA in clinical samples. *Lancet*, 2: 1069-1071.
- Nogales C, Bernal S, Chávez M (1999):** Comparison of the MB/BacT and BACTEC 460 TB systems. *J Clin Microbiol*; 37: 3432.
- Nolan CM, Goldberg SV, Buskin SE (1999):** Hepatotoxicity associated with isoniazid preventive therapy. *JAMA*;281:1014—1018
- Norval P (1999):** Estimate of the global market for rifampicin-containing fixed-dosecombination tablets. *International Journal of Tuberculosis and Lung Disease*, 3: S292–S300.
- NTP (2006):** National Tuberculosis Control Program, Manual of tuberculosis control in Egypt, Ministry of Health and Population, Egypt.
- Ormerod LP, Horsfield N (1996):** Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. *Tuber Lung Dis*;77:37—42
- Oxford University Press (1993):** World Bank Investing in Health: World Development Report. Oxford.
- Pablos-Mendez A (1998):** Global surveillance for antituberculosis drug resistance, 1994–1997. *New England Journal of Medicine*, 338:1641–1649.
- Park CH, Hixon DL, Ferguson CB, Hall SL, Risheim CC, Cook CB (1984):** Rapid recovery of mycobacteria from clinical specimens using automated radiometric technique. *Am J Clin Pathol*; 81: 341-5.
-

Patricia M and Simone E (1993): Severe isoniazid-associated hepatitis. MMWR, 42: 545-547.

Peloquin CA, Henshaw TL, Huitt GW, Berning SE, Nitta AT, James GT (1994): Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy;14:40—46

Pettersson T, Kockars M and Weber T (1984): Pleural fluid adenosine deaminase rheumatoid and systemic lupus erythromatosis. Chest, 86 (2): 273.

Piersimoni C and Scarparo C (2003): Relevance of commercial amplification methods for direct detection of Mycobacterium tuberculosis complex in clinical samples. J Clin Microbiol; 41: 5355-65.

Pinet G. (2001): Good practice in legislation and regulations for TB control: an indicator of political will. Geneva, World Health Organization.

PT and Kubica GP (1985): Public Health Mycrobiology: a Guide for the Level III Laboratory. Centers for disease Control. Atlanta, Georgia.

Rajeswari R (1999): Socio-economic impact of tuberculosis on patients and family in India. International Journal of Tuberculosis and Lung Disease, 3:869–877.

Rastogi, N. and David, H.L. (1993): Mode of action of antituberculous drugs and mechanisms of resisance in M. tuberculosis. Res. Microbiol., 144: 133-143.

- Raviglione MC (1997):** Tuberculosis and HIV: current status in Africa. *AIDS*, 11:S115–S123.
- Rieder HL. (1999):** Epidemiologic basis of tuberculosis control. Paris, International Union Against Tuberculosis and Lung Disease.
- Roberts GD, Koneman EW and Kim YK (1991):** Mycobacterium. In: Balows A., Hausler WJ, Herrmann KL et al. (eds). *Manual of Clinical Microbiology*. 5th ed. Washington, DC American Society for Microbiology, 304.
- Roggkamp A. (2000):** The MB/BacT is a sensitive method of isolating Mycobacterium tuberculosis from clinical specimens in a laboratory with a low rate of isolation. *J Clin Microbiol*; 38: 3133-4.
- Rohner P, Ninet B, Metral C, Emler S, Auckenthaler R (1997):** Evaluation of the MB/BacT system and comparison to the BACTEC 460 system and solid media for isolation of mycobacteria from clinical specimens. *J Clin Microbiol*; 35: 3127-31.
- Rossmann MD and Oner-Eyuboglu AF (1998):** Mycobacterial infection: Clinical presentation and treatment of tuberculosis. In: *Fishman's pulmonary disease and disorder*, Fishman AP., et al. (eds) 4th edition. McGraw-Hill Health Professions Division New-York, pp. 2483.
- Rothfield TG, Bierer WF, Garfield JW (1978):** Isoniazid induction of antinuclear antibodies. *Ann Intern Med*;88:650—652
-

- Rouillon A (1979):** A model for approaching disease control. *Chest*, 96: 739-740.
- Rouillon A, Perdrizet S, Parrot R (1976):** Transmission of tubercle bacilli: the effects of chemotherapy. *Tubercle*, 57:275–299.
- Saitoh H and Yamane N (2000):** Comparative evaluation of BACTEC MGIT 960 System with MB/BacT and egg-based media for recovery of mycobacteria. *Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi*; 11: 19-26.
- Salem E.S., Sobhy K.E., Ali G. (1990):** HLA-phenotyping in adult tuberculous patients (Abstr). *Am Rev. Respir. Dis*, 14 (4): 792.
- Saunderson PR (1995):** An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda. *Social Science and Medicine*, 40:1203–1212.
- Savic B., Sjobring U., Alugupali S., et al. (1992):** Evaluation of peR. tuberculostearic acid analysis, and direct microscopy for the detection of M.TB in sputum. *Infect. Dis*, 166 (5) 1177-80
- Sawert H (1997):** Costs and benefits of improving tuberculosis control: the case of Thailand. *Social Science and Medicine*, 44:1805–1816.
- Sbarbaro JA (1990):** The patient-physician relationship: compliance revisited. *Annals of Allergy*, 64:326–332.
- Seaton A, Seaton D and Leitch AG (1989):** Clinical features of TB. In: Crofton and Douglas *Respiratory Diseases*, 4th (ed). Blackwell, Oxford, UK, pp. 367-422.
- Sense P. (1983):** History of the development of rifampicin. *Respiratory and Infectious Disease*, 5:402–406.
-

- Sharma SK and Liu JJ (2006):** Progress of DOTS in global tuberculosis control. *Lancet*; 367: 951-2.
- Shim SA, Spech J, Glenn JT and Munday B (1989):** Serological means in the diagnosis of pulmonary tuberculosis. *Int Arch Allerg Appl Immunol.*, 114: 28-34.
- Shimao T (1982):** Tuberculosis case-finding. Geneva, World Health Organization (document WHO/TB/82.131).
- Siddiqi SH, Hwangbo CC, Silcox V, Good RC, Snider DE, Jr., Middlebrook G. (1984):** Rapid radiometric methods to detect and differentiate *Mycobacterium tuberculosis*/M.bovis from other mycobacterial species. *Am Rev Respir Dis*; 130: 634-40.
- Snider DE (1982):** The tuberculin skin test. *Am. Rev. Respir. Dis.*, 125 (2): 108.
- Snider DE (1985):** Bacille Calmette- Guerin vaccination and tuberculin skin test. *JAMA* 253:3438.
- Snider DE, Cross FS and Farer LS (1984):** Six-months therapy for pulmonary tuberculosis. *Am Rev Respir Dis.*, 129: 573-579.
- Sonal S and Munsif F (1999):** Clinical policies and protocols. Bureau of tuberculosis control. New York city Department of Health, 33: 501-506.
- Stead WW and Dutt AK (1982):** Chemotherapy for tuberculosis today, *Am Rev Respir Dis*, 125, 94.
- Steele MA and DesPrez RM (1988):** The role of pyrazinamide in tuberculosis chemotherapy. *Chest*;94:845—850
-

- Styblo K (1991):** Selected papers. Vol. 24, Epidemiology of tuberculosis. The Hague, Royal Netherlands Tuberculosis Association.
- Styblo K and Bumgarner R (1991):** Tuberculosis can be controlled with existing technologies: evidence. Tuberculosis Surveillance Research Unit Progress Report, 2:60–72.
- Sumartoji E (1993):** When tuberculosis treatment fails: a social behavioural account of patient adherence. Am Rev Respir Dis., 147: 1311-1320.
- Takahashi H and Foster V (1983):** Detection and recovery of mycobacteria by a radiometric procedure. J Clin Microbiol; 17: 380-1.
- Telenti, A.; Imboden, P.; Marchesi, F. and Lowrie, D. (1993):** Detection of rifampicin resistance mutations in mycobacterium tuberculosis. Lancet, 341: 647.
- Tenover FC, Crawford JT, Huebner RE (1993):** The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol., 31: 767.
- Toman, K. (1969):** Tuberculosis case finding and chemotherapy who Geneva PG Tuberc1, 49:377.
- Tortoli E, Cichero P, Chirillo MG (1998):** Multicentre comparison of ESP Culture System II with BACTEC 460TB and with Lowenstein-Jensen medium for recovery of mycobacteria from different clinical specimens, including blood. J Clin Microbiol; 36: 1378-81.
-

- Trebucq A (1997):** Should Ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. *Int J Tuberc Lung Dis*;1:12—15
- Tuberculosis Control Guide (1998):** A new strategy for TB control: DOTS, National Tuberculosis Control Programme, 2nd edition, Ministry of Health and Population, Egypt, page 1.
- Tuberculosis Control Guide (2000):** Ministry of Health and Population, Egypt.
- United States Pharmacopeial Dispensing Information (1999):** Drug Information for the Health Care Professional. Vol. I. Englewood, CO: Micromedex, 69—1419
- Vareldzis, B.P.; Grosset, J.; Dekantor, I. (1994):** Drug-resistant tuberculosis; laboratory issues, World Health Organization Recommendations. *Tubercle and Lung Disease*, 75: 1-7.
- Vidal, R.; Martin-Casabona, N.; Juan, A. (1996):** Incidence and significance of acid fast bacilli in sputum smears at the end of antituberculous treatment chest 1996 109-1262-1265.
- Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ (1997):** Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. *Am J Respir Crit Care Med*;155:1735—1738
- Walley JD (2001):** Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. *Lancet*, 357:664—669.
-

- Warren N.G. and Body B.A. (1995):** Bacteriology and diagnosis. In: Tuberculosis clinical management and new challenges I" Cd Edited by MD Rossman and RR Macgregor. New York: tvlcGrow-HilJ Inc., Chap 3,p. 35.
- Weinstein HJ, Hallett WY, Sarauw AS (1962):** The absorption and toxicity of ethionamide. Am Rev Respir Dis;86:576—578
- Weis SE, Slocum PC, Blais F, King B and Nunn M (1994):** The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Medn., 330: 1179-1184.
- Whittier PS, Westfall K, Seterquist S and Hopfer RL (1992):** Evaluation of the septichek AFB system in the recovery of mycobacteria. Eur J Clin Microbiol Infect Dis., 11: 915.
- WHO (1974):** WHO Expert Committee on Tuberculosis. Ninth Report. Geneva,World Health Organization, (WHO Technical Report Series, No. 552).
- WHO (1994):** Managing tuberculosis at the district level: a training course. Geneva,World Health Organization, (document WHO/TB/96.211).
- WHO (1995):** Global tuberculosis programme. Stop TB at the source: annual report on the tuberculosis epidemic. Geneva,World Health Organization.
- WHO (1996):** Cambridge, MA, Harvard School of Public Health on behalf of the World Health Organization and the World Bank, (Global Burden of Disease and Injury Series, Vol. I).
-

- WHO (1997a):** Treatment programme and international Union Against Tuberculosis and lung Disease: Guidelines for surveillance of drug resistance in tuberculosis WHO/T.B. 1997. 178. Geneva: World Health Organization 1-24.
- WHO (1997b):** Treatment of tuberculosis: guidelines for national programmes, 2nd edition. WHO/TB/97.220. Geneva, Switzerland.
- WHO (1997c):** Treatment of tuberculosis; Guidelines for National Programmes, 3d ed., 97: 220-225.
- WHO (1998):** Global tuberculosis programme. Report of the tuberculosis epidemic. Geneva, World Health Organization, (document WHO/TB/245).
- WHO (1999a):** What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. Geneva.
- WHO (1999b):** Stop Tuberculosis Initiative. Report by the Director-General. Geneva (document EB105/13).
- WHO (2000a):** Anti-tuberculosis drug resistance in the world. The WHO/IUATLD global project on antituberculosis drug resistance surveillance. Report No.2: prevalence and trends. Geneva, World Health Organization, (document WHO/CDS/TB/2000.278).
- WHO (2000b):** The economic impacts of tuberculosis. Geneva, World Health Organization (document WHO/CDS/STB/2000. 5; Stop TB Initiative series).
- WHO (2001a):** Global tuberculosis control. WHO Report. Geneva, World Health Organization, (document WHO/CDS/TB/287).
-

- WHO (2001b):** Global DOTS expansion plan, progress in TB control in high-burden countries. Geneva, World Health Organization, 2001 (document WHO/CDS/STB/11).
- WHO (2002a).** Expanding DOTS in the context of a changing health system. Geneva, WHO, 2002 (WHO/CDS/TB/2002.318).
- WHO (2002b).** The newsletter of the global partnership movement to Stop TB. 2002; 7.
- WHO (2002c):** An expanded DOTS Framework for Effective Tuberculosis Control. Geneva, World Health Organization, (document WHO/CDS/TB/2002.297).
- WHO (2003a):** Treatment of tuberculosis: guidelines for national programmes, 3rd ed. Geneva.
- WHO (2003b):** Global tuberculosis control. WHO Report 2003. Geneva, World Health Organization, (document WHO/CDS/TB/316).
- WHO (2004a):** Geneva field test, Management of tuberculosis, training for district T.B coordinator.
- WHO (2004b):** Human resources development for TB control: report of a consultation held on 27 and 28 August 2003. World Health Organization/Rockefeller Foundation, Geneva.
- WHO (2005a):** Task Analysis - The basis for development of training in management of tuberculosis. Geneva.
- WHO (2005b):** Million treatments in 4 years. Achievement report - special edition. Geneva.
-

- WHO (2006a).** Global tuberculosis control: surveillance, planning and financing. Geneva, Switzerland: WHO; 2006. Publication WHO/HTM/TB/2006.362.
- WHO (2006b):** Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, World Health Organization.
- WHO (2006c).** Stop TB Partnership. The Stop TB Strategy. Building on and enhancing DOTS to meet the TB-related Millennium Development Goals. Geneva, WHO, 2006 (WHO/HTM/TB/2006.368).
- WHO (2006d).** The Global Plan to Stop TB, 2006-2015. Actions for life-towards a world free of tuberculosis. Geneva, WHO, 2006 (WHO/HTM/STB/2006.35).
- Wilcke .J.T.R., Jenson B.N., Ravn P. (1996):** Clinical evaluation of IvIPT-64 and MPT-59, two proteins secreted from M.TI3 for skin test reagents. Tubere Lung Dis., 77: 250-6.
- Wilkinson D, Davies GR, Connolly C (1996):** Directly observed therapy for tuberculosis in rural South Africa 1991 through 1994. American Journal of Public Health, 86:1094–1097.
- Williams M.H., Yoo a.H. and Kane C. (1973):** Pulmonary function in miliary tuberculosis. Am.Rev.Respir. Dis., 107: 858.
- Williams-Bouyer N, Yorke R, Lee HI, Woods GL (2000):** Comparison of the BACTEC MGIT 960 and ESP Culture System II for growth and detection of mycobacteria. J Clin Microbiol; 38: 4167-70.
-

- Woods GL, Bergmann JS, Williams-Bouyer N (2001):** Clinical evaluation of the Gen-Probe Amplified Mycobacterium tuberculosis Direct Test for rapid detection of Mycobacterium tuberculosis in select nonrespiratory specimens. *J Clin Microbiol*; 39: 747-9.
- Yan J, Huang A, Tsai S, Ko W, Jin Y, Wu J (2000):** Comparison of the MB/BacT and BACTEC MGIT 960 system for recovery of mycobacteria from clinical specimens. *Diagn Microbiol Infect Dis*; 37: 25-30.
- Zhang, Y.; Heym, B.; Alles, B. and Young, D. (1992):** The catalase peroxidase gene and isoniazid resistance of Mycobacterium Tuberculosis: *Nature* 358: 591.
- Zykof M.P., Godovannyi B.A., Donets Y.I. (1966):** Kaolin agglutination test in diagnosis of tuberculosis in Kenya. *Tubercle*. 97:273.
-